Free tool
FAERS Monitor: Stelara
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming BLA 761044 or its brand name (Stelara, Ustekinumab). Reports on generic versions are filed under their own applications.
Reports
103,163
Serious
61,436
60% of reports
Hospitalization
22,763
Death reported
6,203
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug ineffective14,942
- off label use12,880
- product dose omission issue10,242
- fatigue6,966
- psoriasis6,617
- pain6,322
- crohn^s disease5,993
- arthralgia5,902
- rash5,714
- product use issue5,463
- headache5,377
- condition aggravated5,316
- infusion related reaction5,233
- rheumatoid arthritis4,920
- diarrhoea4,806
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2009 | 34 |
| 2010 | 339 |
| 2011 | 836 |
| 2012 | 1,456 |
| 2013 | 1,849 |
| 2014 | 1,704 |
| 2015 | 5,305 |
| 2016 | 4,517 |
| 2017 | 6,660 |
| 2018 | 8,727 |
| 2019 | 10,236 |
| 2020 | 13,325 |
| 2021 | 7,743 |
| 2022 | 9,895 |
| 2023 | 10,036 |
| 2024 | 9,237 |
| 2025 | 7,214 |
| 2026 | 4,050 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 20,950,996 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| infusion related reactionSignal | 5,233 | 17.4 | 16.9 | 74,672 |
| psoriasisSignal | 6,617 | 10.8 | 10.6 | 56,371 |
| rheumatoid arthritisSignal | 4,920 | 9.2 | 8.9 | 34,534 |
| product dose omission issueSignal | 10,242 | 7.3 | 7.2 | 54,709 |
| product use issueSignal | 5,463 | 6.1 | 5.9 | 22,680 |
| condition aggravatedSignal | 5,316 | 3.6 | 3.5 | 10,000 |
| off label useSignal | 12,880 | 3.0 | 3.0 | 17,993 |
| arthralgiaSignal | 5,902 | 2.9 | 2.8 | 7,498 |
| rashSignal | 5,714 | 2.7 | 2.6 | 6,136 |
| drug ineffectiveSignal | 14,942 | 2.3 | 2.3 | 11,919 |
| painSignal | 6,322 | 2.1 | 2.1 | 3,761 |
| fatigue | 6,966 | 1.8 | 1.8 | 2,706 |
| headache | 5,377 | 1.8 | 1.7 | 1,784 |
| diarrhoea | 4,806 | 1.5 | 1.5 | 880 |
| crohn^s disease | 5,993 | 0.0 | 0.0 | 1,217,239 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.